Company Overview
Jasper Therapeutics, Inc. operates as a clinical-stage biotechnology company dedicated to developing therapeutics that specifically target diseases driven by mast cells and hematopoietic stem cells. The company's primary strategic focus centers on its lead product candidate, briquilimab, a monoclonal antibody engineered to block stem cell factor from binding to its receptor and signaling downstream pathways. This entity functions within the broader Healthcare sector and the specialized Biotechnology industry, environments characterized by high research and development expenditures and significant regulatory oversight. Currently, the company employs 27 individuals and holds a market capitalization of $29.38M, reflecting a relatively small-scale operation typical of pre-commercial biotechnology firms. The combination of a modest market cap and the absence of reported annual revenue indicates that the company is in an early development phase where value is derived primarily from intellectual property and potential future clinical outcomes rather than current commercial sales.
Financial Health
The company reported a net income of $-91,021,000 and an EBITDA of $-90,511,000 for the trailing twelve months, while revenue figures are not available for the trailing twelve months period. The substantial negative net income relative to the reported EBITDA suggests that non-operating expenses or interest costs are contributing significantly to the overall loss, widening the gap between operational performance and final profitability. Free cash flow stands at $-42,694,248, indicating that the company is burning cash at a rate that requires continuous external financing to sustain its operations and R&D pipeline. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is standard for clinical-stage biotechs that have not yet generated commercial revenue but highlights the lack of current profitability. On the balance sheet, Jasper Therapeutics holds $50.90M in cash against $1.70M in debt, resulting in a debt-to-equity ratio of 14.72, a figure that appears leveraged but is common for cash-rich, pre-revenue companies where debt levels are intentionally kept low to preserve flexibility. The current ratio is 2.59, suggesting that the company possesses sufficient liquid assets to cover its short-term obligations more than twice over, providing a buffer against immediate liquidity crises. Furthermore, the return on equity is -191.1% and the return on assets is -72.9%, metrics that mathematically reflect the heavy investment in development costs relative to the company's existing equity and asset base rather than indicating operational inefficiency.
Valuation Assessment
The trailing twelve-month P/E ratio is not available, while the forward P/E is listed as -0.44, a negative figure that implies earnings are expected to remain negative or that the valuation model relies on projected earnings that have not yet materialized. The price-to-book ratio is 2.54, indicating that the market values the company at a premium of 2.54 times its net asset value, a common valuation multiple for biotechnology firms with significant intangible assets and high growth potential despite current losses. Alternative valuation metrics such as the price-to-sales ratio are not available due to a lack of revenue data, while the EV/EBITDA stands at 0.22, suggesting a very low enterprise value relative to earnings before interest, taxes, depreciation, and amortization when adjusted for the company's negative earnings. The stock has traded between a 52-week low of $1.04 and a 52-week high of $7.19, with the current trading price situated within this historical range but closer to the lower end given the negative forward earnings multiple. The beta value is 3.12, which signifies that the stock's price volatility is more than three times that of the broader market, exposing investors to significant fluctuations in share price during periods of market stress or rally.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available, reflecting the company's status as a pre-revenue entity where historical growth rates cannot be calculated from financial statements. Since the company does not pay a dividend, the dividend yield is not applicable and the payout ratio is 0.0%, meaning all available cash flow is retained and reinvested into research and development activities rather than distributed to shareholders. The absence of a dividend yield confirms that the company follows a growth-oriented capital allocation strategy, prioritizing the advancement of its clinical pipeline over providing current income to investors. Consequently, the overall growth and income profile is defined entirely by the potential future commercialization of its pipeline and the ability to extend its cash runway, rather than by current earnings growth or dividend distributions.